---
id: 249
title: Pneumocystis jirovecii (PCP)
category: organisms
subcategory: fungi
tags: [PCP, Pneumocystis, TMP-SMX, HIV, CD4, steroids, prophylaxis]
difficulty: high
---

## Question

What are key clinical syndromes and treatment considerations for *Pneumocystis jirovecii*? Use **"HIV CD4 <200: TMP-SMX Treatment + Steroids if PaO₂ <70, Prophylaxis TMP-SMX DS Daily"** framework.

## Answer

### **Epidemiology:**

- **Fungus** (formerly classified as protozoan)
- **Ubiquitous** (most humans exposed by age 3-4)
- **Reactivation** in immunocompromised
- **Airborne transmission** (person-to-person possible)

### **Risk Factors:**

**HIV:**
- **CD4 <200 cells/μL** (highest risk)
- **Most common AIDS-defining illness** (before widespread ART/prophylaxis)

**Non-HIV Immunosuppression:**
- **Hematologic malignancy** (lymphoma, leukemia)
- **Solid organ/HSCT transplant**
- **High-dose steroids** (>20 mg prednisone × >1 month)
- **Chemotherapy** (especially with T-cell depletion)
- **Anti-TNF, anti-CD20** (rituximab, infliximab)

### **Clinical Presentation:**

**HIV-Associated PCP:**
- **Subacute onset** (weeks)
- **Progressive dyspnea** (exertional → at rest)
- **Dry cough** (non-productive)
- **Fever**
- **Chest discomfort**
- **Hypoxemia** (↓PaO₂, ↑A-a gradient)

**Non-HIV PCP:**
- **More acute** (days)
- **Severe hypoxemia** (more fulminant)
- **Higher mortality** (30-50% vs 10-20% in HIV)

**Physical Exam:**
- **Often unremarkable** (clear lungs)
- **Tachypnea, hypoxemia**

### **Diagnosis:**

**Chest X-Ray:**
- **Bilateral interstitial/perihilar infiltrates** ("bat-wing")
- **Can be normal** (5-10%, especially early)
- **Atypical:** Nodules, cavitation, pneumothorax (especially with aerosolized pentamidine prophylaxis)

**CT Chest:**
- **Ground-glass opacities** (diffuse, bilateral)
- **More sensitive** than CXR

**Arterial Blood Gas:**
- **Hypoxemia** (PaO₂ <70 mmHg)
- **↑A-a gradient** (>35 mmHg)
- **Exercise desaturation** (if borderline at rest)

**Microbiologic Diagnosis:**

**Induced Sputum:**
- **Immunofluorescence (DFA), PCR, Giemsa/GMS stain**
- **Sensitivity 50-90%** (depends on expertise, HIV status)

**Bronchoalveolar Lavage (BAL):**
- **Gold standard** (sensitivity >95%)
- **If induced sputum negative** or high clinical suspicion

**β-D-Glucan:**
- **Serum assay** (elevated in PCP, but also other fungi)
- **High sensitivity** (90-95%), lower specificity
- **Useful as adjunct** (if high + compatible clinical picture, can start empiric treatment)

**Organism Characteristics:**
- **Trophic forms, cysts** (cannot culture on routine media)
- **GMS stain** (cysts), **Giemsa stain** (trophozoites)

### **Treatment:**

**Preferred (Moderate-Severe, PaO₂ <70 mmHg or A-a >35):**

- **TMP-SMX 15-20 mg/kg/day (TMP component) IV divided q6-8h × 21 days**
  - **Example:** TMP-SMX 5 mg/kg (TMP component) IV q6h
- **+ Prednisone 40mg PO BID × 5 days → 40mg daily × 5 days → 20mg daily × 11 days** (total 21 days)
  - **Start within 72h of antibiotics** (if PaO₂ <70 mmHg or A-a >35)
  - **Reduces mortality, respiratory failure**

**Step-Down to PO:**
- **After clinical improvement** (usually 7-10 days)
- **TMP-SMX DS 2 tablets PO TID × total 21 days**

**Mild (PaO₂ ≥70 mmHg, A-a ≤35):**
- **TMP-SMX DS 2 tablets PO TID × 21 days**
- **No steroids** (not indicated if mild)

**Alternative Regimens (If TMP-SMX Intolerant):**

**Moderate-Severe:**
- **Pentamidine 4 mg/kg IV daily × 21 days** (nephrotoxic, hypotension, hypoglycemia)
- **Primaquine 30mg (base) PO daily + clindamycin 600-900mg IV q6-8h × 21 days** (check G6PD first)

**Mild:**
- **Atovaquone 750mg PO BID × 21 days** (with food, high-fat meal)
- **Primaquine 30mg (base) PO daily + clindamycin 300-450mg PO TID × 21 days**

**Duration:** **21 days** (standard, regardless of regimen)

### **Adjunctive Steroids:**

**Indications:**
- **PaO₂ <70 mmHg** on room air OR **A-a gradient >35 mmHg**
- **Start within 72h** of antibiotic initiation

**Regimen:**
- **Prednisone 40mg PO BID × 5 days**
- **Then 40mg PO daily × 5 days**
- **Then 20mg PO daily × 11 days** (total 21 days)

**Benefits:**
- **Reduces mortality** (NNT ~6)
- **Reduces respiratory failure, need for mechanical ventilation**

### **Prophylaxis:**

**Primary Prophylaxis (Prevent First Episode):**

**Indications (HIV):**
- **CD4 <200 cells/μL** OR **<14%**
- **Oropharyngeal candidiasis** (regardless of CD4)
- **CD4 200-250** if cannot monitor regularly

**Indications (Non-HIV):**
- **Hematologic malignancy** (especially ALL with chemotherapy)
- **Solid organ/HSCT transplant** (first 3-6 months)
- **Prednisone >20 mg/day × >1 month** (especially with other immunosuppression)
- **Anti-CD20 therapy** (rituximab)

**Preferred:**
- **TMP-SMX DS 1 tablet PO daily** (or 3×/week if adherence/tolerance issue)

**Alternatives:**
- **Dapsone 100mg PO daily** (check G6PD first)
- **Atovaquone 1500mg PO daily**
- **Aerosolized pentamidine 300mg monthly** (via nebulizer, less effective, atypical presentations)

**Secondary Prophylaxis (Prevent Recurrence):**
- **After completing treatment:** Continue prophylaxis (same as primary)

**Discontinuing Prophylaxis (HIV):**
- **CD4 >200 cells/μL × 3 months** on ART
- **Can restart** if CD4 drops <200

### **Complications:**

**Pneumothorax:**
- **5-10%** (especially with cystic changes, aerosolized pentamidine prophylaxis)
- **Often bilateral, recurrent**
- **May require chest tube, pleurodesis**

**Respiratory Failure:**
- **10-30%** require mechanical ventilation
- **High mortality** if intubated (50-70%)

### **Prognosis:**

**Mortality:**
- **HIV (treated):** 10-20%
- **Non-HIV (treated):** 30-50% (higher, more fulminant)
- **Mechanical ventilation:** 50-70% mortality

**Predictors of Poor Outcome:**
- **Severe hypoxemia** (PaO₂ <50 mmHg)
- **Non-HIV immunosuppression**
- **Mechanical ventilation**
- **Elevated LDH** (>500 U/L)

## Key Points

### **CD4 <200 = High Risk (HIV):**
- **Prophylaxis:** TMP-SMX DS daily

### **Treatment: TMP-SMX × 21 Days:**
- **TMP-SMX 15-20 mg/kg/day (TMP component) IV divided q6-8h**

### **Steroids if PaO₂ <70:**
- **Prednisone 40mg BID × 5d → 40mg daily × 5d → 20mg daily × 11d**
- **Start within 72h** of antibiotics
- **Reduces mortality**

### **BAL = Gold Standard:**
- **Sensitivity >95%**
- **Induced sputum 50-90%** (less sensitive)

### **Non-HIV = More Severe:**
- **More acute, fulminant**
- **Higher mortality** (30-50%)

### **Clinical Pearls:**
- **Prophylaxis:** TMP-SMX DS daily (if CD4 <200)
- **Treatment:** TMP-SMX 15-20 mg/kg/day (TMP) IV q6-8h × 21 days
- **Steroids:** Prednisone taper (if PaO₂ <70 or A-a >35, start within 72h)
- **BAL gold standard** (>95% sensitivity)
- **Non-HIV:** More severe, higher mortality (30-50%)
- **β-D-glucan:** High sensitivity (adjunct to diagnosis)

## Sources

- [IDSA: PCP Guidelines 2024]
- [CID: Pneumocystis Pneumonia Management 2024]

## Media

N/A
